JP2023545229A5 - - Google Patents

Info

Publication number
JP2023545229A5
JP2023545229A5 JP2022573176A JP2022573176A JP2023545229A5 JP 2023545229 A5 JP2023545229 A5 JP 2023545229A5 JP 2022573176 A JP2022573176 A JP 2022573176A JP 2022573176 A JP2022573176 A JP 2022573176A JP 2023545229 A5 JP2023545229 A5 JP 2023545229A5
Authority
JP
Japan
Prior art keywords
isolated polynucleotide
amd
vector
complement
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545229A (ja
Filing date
Publication date
Priority claimed from GBGB2016463.8A external-priority patent/GB202016463D0/en
Priority claimed from GBGB2104148.8A external-priority patent/GB202104148D0/en
Application filed filed Critical
Priority claimed from PCT/GB2021/052689 external-priority patent/WO2022079453A1/en
Publication of JP2023545229A publication Critical patent/JP2023545229A/ja
Publication of JP2023545229A5 publication Critical patent/JP2023545229A5/ja
Pending legal-status Critical Current

Links

JP2022573176A 2020-10-16 2021-10-18 抗vegf実体および負の補体調節因子をコードする核酸、ならびに加齢黄斑変性の処置のためのその使用 Pending JP2023545229A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2016463.8 2020-10-16
GBGB2016463.8A GB202016463D0 (en) 2020-10-16 2020-10-16 Product
GB2104148.8 2021-03-24
GBGB2104148.8A GB202104148D0 (en) 2021-03-24 2021-03-24 Product
PCT/GB2021/052689 WO2022079453A1 (en) 2020-10-16 2021-10-18 Nucleic acid encoding an anti-vegf entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration

Publications (2)

Publication Number Publication Date
JP2023545229A JP2023545229A (ja) 2023-10-27
JP2023545229A5 true JP2023545229A5 (cg-RX-API-DMAC7.html) 2024-10-28

Family

ID=78463555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573176A Pending JP2023545229A (ja) 2020-10-16 2021-10-18 抗vegf実体および負の補体調節因子をコードする核酸、ならびに加齢黄斑変性の処置のためのその使用

Country Status (18)

Country Link
US (1) US20230212275A1 (cg-RX-API-DMAC7.html)
EP (1) EP4229076A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023545229A (cg-RX-API-DMAC7.html)
KR (1) KR20230088630A (cg-RX-API-DMAC7.html)
CN (1) CN119585299A (cg-RX-API-DMAC7.html)
AU (1) AU2021362770A1 (cg-RX-API-DMAC7.html)
CA (1) CA3182337A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001072A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023005981A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230202A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000076A (cg-RX-API-DMAC7.html)
EC (1) ECSP23034907A (cg-RX-API-DMAC7.html)
IL (1) IL298527A (cg-RX-API-DMAC7.html)
JO (1) JOP20230076A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023004377A (cg-RX-API-DMAC7.html)
PE (1) PE20231747A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023551015A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022079453A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB201821089D0 (en) 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
AU2021313839A1 (en) * 2020-07-21 2023-03-23 FTGEN Corp Composition and method for treating eye diseases
WO2025083169A1 (en) * 2023-10-17 2025-04-24 Tenpoint Therapeutics Limited Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders
KR20260004635A (ko) * 2024-07-01 2026-01-09 삼성바이오에피스 주식회사 애플리버셉트를 암호화하는 코돈-최적화된 폴리뉴클레오티드를 포함하는 발현 카세트 및 이를 포함하는 rAAV 생산용 플라스미드

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745389B2 (en) * 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US20100004316A1 (en) * 2006-09-29 2010-01-07 University Of Utah Research Foundation Multifunctional carriers for the delivery of nucleic acids and methods of use thereof
ATE498008T1 (de) * 2006-10-23 2011-02-15 Res Org Information & Systems Verfahren zur herstellung eines zellstamms mit fähigkeit zur tetracyclin-induzierten genexpression oder eines zellstamms mit konditionalem gen-knockout sowie verwendung der zellstämme
DK2623605T3 (en) 2007-04-09 2019-03-25 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
EP3683314A1 (en) * 2013-10-07 2020-07-22 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
IL262207B2 (en) * 2016-04-15 2026-01-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
MX2020003945A (es) * 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
CN111788311A (zh) * 2017-10-20 2020-10-16 双子治疗公司 用于治疗年龄相关性黄斑变性的组合物和方法
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
GB201821089D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
MX2022004939A (es) * 2019-10-23 2022-08-10 Gemini Therapeutics Sub Inc Metodos para tratar pacientes que tienen mutaciones de cfh con proteinas de cfh recombinantes.

Similar Documents

Publication Publication Date Title
JP2021503914A5 (cg-RX-API-DMAC7.html)
JP2022141670A5 (cg-RX-API-DMAC7.html)
JP6387350B2 (ja) 希突起神経膠細胞を標的とするアデノ随伴ウイルスベクター
FI3717636T3 (fi) Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
JP2025000642A5 (cg-RX-API-DMAC7.html)
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
JP2023545722A5 (cg-RX-API-DMAC7.html)
CN117467025B (zh) 一种抗vegf和补体双功能融合蛋白及其应用
JP2022522776A5 (cg-RX-API-DMAC7.html)
CN114480440A (zh) 靶向中枢神经系统的aav载体
JP2015523060A5 (cg-RX-API-DMAC7.html)
JP2021511030A5 (cg-RX-API-DMAC7.html)
CN113286878A (zh) 补体因子i和补体因子i辅因子、编码它们的载体和治疗用途
US20150182638A1 (en) Virus-mediated delivery of bevacizumab for therapeutic applications
TWI923758B (zh) 用於治療與血管生成相關的眼部疾病的組合物和方法
US20230212275A1 (en) Nucleic acid encoding an anti-vegf entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration
JP2025501286A (ja) 修飾されたaavカプシドタンパク質及びその使用
US20240358855A1 (en) Multigene constructs for treatment of age-related macular degeneration and other complement dysregulation-related conditions
IL312657A (en) Codon-optimised complement factor i
AU2024261900A1 (en) Nucleic acid encoding anti-vegf protein, polynucleotide expression cassette and recombinant adeno-associated virus
US20240279324A1 (en) Multispecific antagonists
EP4368203A1 (en) Construction and use of anti-vegf antibody in-vivo expression system
JP2022523050A5 (cg-RX-API-DMAC7.html)
RU2021119359A (ru) Фактор комплемента i и кофактор фактора комплемента i, кодирующие их векторы и применение в терапевтических целях
EP4703378A1 (en) Drug for relieving ocular angiogenesis related diseases and use thereof